In a report released today, Ryan Zimmerman from BTIG maintained a Hold rating on Zimmer Biomet Holdings (ZBH). The company’s shares closed last Monday at $138.79, close to its 52-week high of $143.57.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 21.8% and a 61.3% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Integra Lifesciences, OrthoPediatrics Corp, and Stryker Corporation.
Currently, the analyst consensus on Zimmer Biomet Holdings is a Moderate Buy with an average price target of $146.71.
See today’s analyst top recommended stocks >>
Based on Zimmer Biomet Holdings’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $134 million. In comparison, last year the company had a net profit of $185 million.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZBH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zimmer Biomet Holdings, Inc. provides musculoskeletal healthcare services. It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products.
